CooperCompanies Announces Second Quarter 2026 Results

Revenue up, but litigation costs hammered profits and operating margins turned negative.

What the company is saying

CooperCompanies is positioning itself as a resilient healthcare player that can deliver growth despite recent setbacks. The company’s core narrative emphasizes an 8% year-over-year revenue increase to $1.082 billion and a 26% rise in non-GAAP EPS, framing these as evidence of underlying business strength. Management is explicit about the $271.6 million litigation-related charge tied to a December 2023 product recall at CooperSurgical, but they present this as a one-off event rather than a recurring issue. The announcement highlights stable gross margins (68%) and positive free cash flow ($96.4 million), aiming to reassure investors about operational health. Forward-looking statements focus on fiscal 2026 guidance: total revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66, with a reaffirmed long-term free cash flow target exceeding $2.2 billion for 2026–2028. The tone is neutral and factual, with little promotional language; management projects confidence by providing detailed segment breakdowns and reiterating prior guidance. Al White, CooperCompanies’ President and CEO, is the only notable individual mentioned, and his involvement signals continuity and accountability at the top. The narrative fits a broader investor relations strategy of transparency about extraordinary items while steering attention to core growth metrics and future targets. Compared to prior communications (where available), there is no evidence of a dramatic shift in messaging, but the explicit discussion of litigation costs is more prominent than typical for a standard quarter.

What the data suggests

The numbers show a mixed picture: revenue for the quarter was $1.082 billion, up 8% year-over-year, with organic growth at 5%. Non-GAAP diluted EPS rose 26% to $1.21, but GAAP diluted EPS fell sharply to $(0.40), a drop of $0.84 from the prior year, due to the $271.6 million litigation charge. Operating margin collapsed from 18% last year to negative 3% this quarter, directly reflecting the impact of the recall-related charge, while gross margin held steady at 68%. Free cash flow was positive at $96.4 million, calculated from $182.8 million in operating cash flow minus $86.4 million in capital expenditures. Segment data shows CooperVision revenue up 8% to $723.5 million, with strong growth in EMEA (+17%) but a 6% decline in Asia Pacific, and CooperSurgical revenue up 8% to $358.0 million, with fertility products up 13%. The gap between the company’s growth narrative and the numbers is most evident in profitability: while top-line and non-GAAP metrics look healthy, GAAP results and operating margins are severely impacted by the litigation charge. Prior targets for revenue growth appear to be met, but the lack of prior period non-GAAP operating margin figures limits full transparency. Financial disclosures are generally comprehensive, but some non-GAAP and programmatic details (like the repurchase program’s total size) are not fully spelled out. An independent analyst would conclude that, while the core business is growing, the company’s profitability and risk profile have deteriorated due to extraordinary legal costs.

Analysis

The announcement is a standard quarterly financial disclosure, with the majority of claims focused on realised, historical results for the second quarter of 2026. Forward-looking statements are limited to fiscal 2026 revenue and EPS guidance, as well as a reiterated long-term free cash flow objective. These projections are typical for quarterly reporting and are not presented with exaggerated or promotional language. The tone is factual, and there is no evidence of narrative inflation or overstatement relative to the disclosed numbers. Capital expenditures and litigation charges are clearly quantified and tied to realised impacts, not aspirational outcomes. There is no indication of a large capital outlay paired with only long-dated, uncertain returns.

Risk flags

• ●Litigation and recall risk is acute: The $271.6 million charge tied to the December 2023 CooperSurgical recall demonstrates that product quality issues can have a massive, immediate impact on profitability. Investors must consider the possibility of further legal or regulatory fallout, especially if additional claims arise.
• ●Profitability volatility: Operating margin swung from 18% last year to negative 3% this quarter, showing that even a single extraordinary event can erase operating profits. This volatility undermines confidence in the company’s ability to deliver consistent returns.
• ●Heavy reliance on non-GAAP metrics: The company’s narrative leans on non-GAAP EPS and operating margin improvements, but these exclude material litigation costs. Investors risk being misled if they focus only on adjusted figures and ignore the true GAAP results.
• ●Geographic performance divergence: While EMEA revenue grew 17%, Asia Pacific revenue declined 6%. This uneven performance could signal market-specific challenges or competitive pressures that may persist or worsen.
• ●Execution risk on long-term targets: The reaffirmed free cash flow objective exceeding $2.2 billion for 2026–2028 is a multi-year goal, and there is no guarantee that future periods will not be hit by further extraordinary charges or operational setbacks.
• ●Capital allocation risk: The company spent $13.1 million on share repurchases this quarter and has $860.8 million remaining in the program, but with profitability under pressure, there is a risk that buybacks could crowd out investment in core operations or risk management.
• ●Disclosure gaps: Some non-GAAP comparisons lack prior period figures, and the mechanics of the litigation charge (how $324.1 million in liabilities and $52.5 million in insurance recoveries net to $271.6 million) are not fully detailed. This limits transparency and makes it harder for investors to independently verify management’s narrative.
• ●Concentration of leadership: Al White, as President and CEO, is the only notable individual identified. While this signals accountability, it also means that strategic direction is highly dependent on a single executive, increasing key-person risk if leadership changes or if his judgment is called into question.

Bottom line

For investors, this announcement means CooperCompanies is growing revenue and maintaining strong gross margins, but its profitability has been severely impacted by a major litigation charge tied to a product recall. The company’s narrative is credible in terms of top-line growth and operational cash flow, but the reliance on non-GAAP metrics to paint a positive picture masks the true extent of the hit to GAAP earnings and operating margin. Al White’s continued leadership provides stability, but does not guarantee that further legal or operational surprises are off the table. To change this assessment, the company would need to demonstrate that litigation risks are fully contained and provide more granular disclosure on non-GAAP adjustments and the mechanics of extraordinary charges. Key metrics to watch in the next quarter are GAAP operating margin, any new litigation or recall disclosures, and whether revenue growth continues in all regions, especially Asia Pacific. Investors should monitor this situation closely rather than act immediately: the signal is mixed, with strong core growth offset by real risks to profitability and transparency. The single most important takeaway is that while CooperCompanies’ underlying business is growing, extraordinary legal costs have exposed the company’s vulnerability to operational shocks, and future profitability is far from assured.

Announcement summary

(NASDAQ:COO) CooperCompanies announced financial results for its fiscal second quarter ended April 30, 2026, reporting revenue of $1.082 billion, up 8% from last year's second quarter. Second quarter 2026 GAAP diluted earnings per share (EPS) was $(0.40), down $0.84 from last year's second quarter, primarily due to a $271.6 million litigation-related charge associated with a December 2023 voluntary product recall at CooperSurgical. Non-GAAP diluted EPS for the quarter was $1.21, up $0.25 or 26% from last year's second quarter. Gross margin was 68%, similar to last year's second quarter, and operating margin was negative 3% compared with 18% in last year’s second quarter. Cash provided by operations was $182.8 million, offset by capital expenditures of $86.4 million, resulting in free cash flow of $96.4 million. The company repurchased $13.1 million of common stock, approximately 174 thousand shares, at an average share price of $75.84. The company projects fiscal 2026 total revenue of $4.285 - $4.321 billion, CVI revenue of $2.883 - $2.908 billion, CSI revenue of $1.402 - $1.414 billion, and non-GAAP diluted EPS of $4.58 - $4.66.

Disagree with this article?